ArticleBreast cancer research : BCR2011
Variants on the promoter region of PTEN affect breast cancer progression and patient survival.
Article in Breast cancer research : BCR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Impact of germline genetic variation on breast cancer prognosis: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- The Significance of SIX1 as a Prognostic Biomarker for Survival Outcome in Various Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2021Pooled it
- Pooled it
- Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Trial
- A retrospective analysis suggests PTEN expression is associated with favorable clinicopathological features of breast cancer.Scientific reports · 2024Article
- The interplay of PTEN and AKT nexus in breast cancer: a molecular perspective.Molecular biology reports · 2024Article
- Mir-183 functions as an oncogene via decreasing PTEN in breast cancer cells.Scientific reports · 2023Article
- Article
- Analysis of m6A Methylation Modification Patterns and Tumor Immune Microenvironment in Breast Cancer.Frontiers in cell and developmental biology · 2022Article
- LncRNA AY343892 inhibits breast cancer development by positively regulating BRCA1-mediated transcription of PTEN.Histology and histopathology · 2020Article
- Genetic interactions between INPP4B and RAD50 is prognostic of breast cancer survival.Bioscience reports · 2020Article
- OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts.Frontiers in oncology · 2019Article
- Parsimonious Gene Correlation Network Analysis (PGCNA): a tool to define modular gene co-expression for refined molecular stratification in cancer.NPJ systems biology and applications · 2019Article
- BRCA1 and BRCA2 5' noncoding region variants identified in breast cancer patients alter promoter activity and protein binding.Human mutation · 2018Article
- PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer.Journal of experimental & clinical cancer research : CR · 2017Article
- DACH1 suppresses breast cancer as a negative regulator of CD44.Scientific reports · 2017Article
- Overexpression of Uridine-Cytidine Kinase 2 Correlates with Breast Cancer Progression and Poor Prognosis.Journal of breast cancer · 2017Article
- Targeting of CCBE1 by miR-330-3p in human breast cancer promotes metastasis.British journal of cancer · 2017Article
- Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium.Breast cancer research : BCR · 2016Article
- Maitake Pro4X has anti-cancer activity and prevents oncogenesis in BALBc mice.Cancer medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe PTEN gene, a regulator of the phosphatidylinositol-3-kinase (PI3K)/Akt oncogenic pathway, is mutated in various cancers and its expression has been associated with tumor progression in a dose-dependent fashion. We investigated the effect of germline variation in the promoter region of the PTEN gene on clinical characteristics and survival in breast cancer.
methodsWe screened the promoter region of the PTEN gene for germline variation in 330 familial breast cancer cases and further determined the genotypes of three detected PTEN promoter polymorphisms -903GA, -975GC, and -1026CA in a total of 2,412 breast cancer patients to evaluate the effects of the variants on tumor characteristics and disease outcome. We compared the gene expression profiles in breast cancers of 10 variant carriers and 10 matched non-carriers and performed further survival analyses based on the differentially expressed genes.
resultsAll three promoter variants associated with worse prognosis. The Cox's regression hazard ratio for 10-year breast cancer specific survival in multivariate analysis was 2.01 (95% CI 1.17 to 3.46) P = 0.0119, and for 5-year breast cancer death or distant metastasis free survival 1.79 (95% CI 1.03 to 3.11) P = 0.0381 for the variant carriers, indicating PTEN promoter variants as an independent prognostic factor. The breast tumors from the promoter variant carriers exhibited a similar gene expression signature of 160 differentially expressed genes compared to matched non-carrier tumors. The signature further stratified patients into two groups with different recurrence free survival in independent breast cancer gene expression data sets.
conclusionsInherited variation in the PTEN promoter region affects the tumor progression and gene expression profile in breast cancer. Further studies are warranted to establish PTEN promoter variants as clinical markers for prognosis in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.